12 patients (34.28%) dropped out si

12例患者（34.28％）退出了研究。这些数据与早期的开放标签的52周研究（Wohlreich等，2004）的发现略有不同，该研究中副作用出现的辍学率为27％。与Wise等人进行的研究相似。（2007），在我们的工作中，一个受试者因无效而停用度洛西汀。停止出现副作用是尽早发生的（42.86％的病例在1个月内）。这一发现与文献中已经知道的一致（Wohlreich等，2007）。在我们的样本中，高比例的样本发生了副作用（停止治疗的患者中占85.71％）。最常见的副作用是恶心（20％），口干（14.29％）和焦虑症（11.43％）。这些数据反映了文献中其他著作的报道（Raskin et al。，2007; Wohlreich et al。，2007; Volonteri等，2010）。DLX已被证明是具有良好安全性的药物。该研究存在一些局限性，需要加以认识。特别是，样本量少和辍学率高可能限制了某些结果的可靠性。此外，在不同的药物多疗程方案中频繁使用度洛西汀可能是评估副作用的一个混杂因素，因此需要针对标准疗法中度洛西汀的耐受性进行研究。另一个限制是缺乏用于比较结果的安慰剂对照。最后，鉴于这是一项自然，开放标签的研究，而不是随机对照试验，因此在观察结果时应谨慎。DLX已被证明是具有良好安全性的药物。该研究存在一些局限性，需要加以认识。特别是，样本量少和辍学率高可能限制了某些结果的可靠性。此外，在不同的药物多疗程方案中频繁使用度洛西汀可能是评估副作用的一个混杂因素，因此需要针对标准疗法中度洛西汀的耐受性进行研究。另一个限制是缺乏用于比较结果的安慰剂对照。最后，鉴于这是一项自然，开放标签的研究，而不是随机对照试验，因此在观察结果时应谨慎。DLX已被证明是具有良好安全性的药物。该研究存在一些局限性，需要加以认识。特别是，样本量少和辍学率高可能限制了某些结果的可靠性。此外，在不同的药物多疗程方案中频繁使用度洛西汀可能是评估副作用的一个混杂因素，因此需要针对标准疗法中度洛西汀的耐受性进行研究。另一个限制是缺乏用于比较结果的安慰剂对照。最后，鉴于这是一项自然，开放标签的研究，而不是随机对照试验，因此在观察结果时应谨慎。特别是，样本量少和辍学率高可能限制了某些结果的可靠性。此外，在不同的药物多疗程方案中频繁使用度洛西汀可能是评估副作用的一个混杂因素，因此需要针对标准疗法中度洛西汀的耐受性进行研究。另一个限制是缺乏用于比较结果的安慰剂对照。最后，鉴于这是一项自然，开放标签的研究，而不是随机对照试验，因此在观察结果时应谨慎。特别是，样本量少和辍学率高可能限制了某些结果的可靠性。此外，在不同的药物多疗程方案中频繁使用度洛西汀可能是评估副作用的一个混杂因素，因此需要针对标准疗法中度洛西汀的耐受性进行研究。另一个限制是缺乏用于比较结果的安慰剂对照。最后，鉴于这是一项自然，开放标签的研究，而不是随机对照试验，因此在观察结果时应谨慎。在不同的药物综合治疗方案中频繁使用度洛西汀可能是评估副作用的一个混杂因素，因此需要针对标准疗法中度洛西汀的耐受性进行研究。另一个限制是缺乏用于比较结果的安慰剂对照。最后，鉴于这是一项自然，开放标签的研究，而不是随机对照试验，因此在观察结果时应谨慎。在不同的药物综合治疗方案中频繁使用度洛西汀可能是评估副作用的一个混杂因素，因此需要针对标准疗法中度洛西汀的耐受性进行研究。另一个限制是缺乏用于比较结果的安慰剂对照。最后，鉴于这是一项自然，开放标签的研究，而不是随机对照试验，因此在观察结果时应谨慎。

12 patients (34.28%) dropped out side effects. These data differ slightly with the findings of an earlier open-label 52-week study (Wohlreich et al., 2004), in which the drop out rate for the appear-ance of side effects was 27%. Similar to the study con-ducted by Wise et al. (2007), in our work, one subject discontinued duloxetine for ineffectiveness. Discontin-uation for the appearance of side effects occurs early (within 1 month in 42.86% of cases). This finding agrees with what is already known in the literature (Wohlreich et al., 2007). In our sample, the side effects have occurred in a high percentage of the sample (85.71% out of patients that discontinued therapy). The most common side effects were nausea (20%), dry mouth (14.29%) and anxiety (11.43%). These data reflect what is reported in other works in the literature (Raskin et al., 2007; Wohlreich et al., 2007; Volonteri et al., 2010). DLX has been shown to be a drug with a good safety profile. The study has some limitations that need to be acknowledged. In particular, the small sample and the high dropout rate might have limited the reliability of some results. In addition, the frequent administration of duloxetine within different medical polytherapy regimens might represent a confounding factor in the evaluation of side effects, so that studies focused on the tolerability of duloxetine within stan-dardized treatments are required. Another limit is the lack of a placebo control for the comparison of the re-sults. Finally, given that this was a naturalistic, open-label study and not a randomized controlled trial, cau-tion should be taken when looking at the results.

12 patients (34.28%) dropped out side effects. These data differ slightly with the findings of an earlier open-label 52-week study (Wohlreich et al., 2004), in which the drop out rate for the appear-ance of side effects was 27%. Similar to the study con-ducted by Wise et al. (2007), in our work, one subject discontinued duloxetine for ineffectiveness. Discontin-uation for the appearance of side effects occurs early (within 1 month in 42.86% of cases). This finding agrees with what is already known in the literature (Wohlreich et al., 2007). In our sample, the side effects have occurred in a high percentage of the sample (85.71% out of patients that discontinued therapy). The most common side effects were nausea (20%), dry mouth (14.29%) and anxiety (11.43%). These data reflect what is reported in other works in the literature (Raskin et al., 2007; Wohlreich et al., 2007; Volonteri et al., 2010). DLX has been shown to be a drug with a good safety profile. The study has some limitations that need to be acknowledged. In particular, the small sample and the high dropout rate might have limited the reliability of some results. In addition, the frequent administration of duloxetine within different medical polytherapy regimens might represent a confounding factor in the evaluation of side effects, so that studies focused on the tolerability of duloxetine within stan-dardized treatments are required. Another limit is the lack of a placebo control for the comparison of the re-sults. Finally, given that this was a naturalistic, open-label study and not a randomized controlled trial, cau-tion should be taken when looking at the results.<br>